Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P480: The effect of adjuvant therapy (Sinergin®) in induction and maintaining remission in mild and moderate IBD

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ichim*1, A. Dimitriu1, C. Gheorghe1, M. Diculescu1, B. Mateescu2, C. Cijevschi Prelipcean3, L. Gheorghe1

1Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania, 2Colentina Hospital, Bucharest, Romania, 3‘Saint Spiridon’ Hospital, Iasi, Romania

P481: Efficacy of the sequential use of a second biologic agent for Crohn’s disease treatment in a non-academic tertiary centre

ECCO '19 Copenhagen

Year: 2019
Authors:

J. C. Silva*1, A. P. Silva1, A. Rodrigues1, C. Fernandes1, A. Ponte1, J. Rodrigues1, M. Sousa1, A. C. Gomes1, J. Carvalho1

1Centro Hospitalar Vila Nova de Gaia/Espinho, Gastroenterology, Vila Nova de Gaia, Portugal

P482: Selective prophylactic anti-tuberculosis strategy is superior for Chinese patients with inflammatory bowel disease receiving infliximab treatment: a multi-centre retrospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

L. Ye*1, M. Chen2, X. Gao3, K. Wu4, Z. Ran5, H. Yang6, Z. Liu7, Q. Cao8

1Xiasha Branch of Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Gastroenterology, Hangzhou, China, 2The First Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China, 3The Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China, 4Xijing Hospital of The Fourth Military Medical University, Gastroenterology, Xi’an, China, 5Renji Hospital, School of Medicine, Shanghai Jiaotong University, Gastroenterology, Shanghai, China, 6Peking Union Medical College Hospital, Gastroenterology, Beijing, China, 7The Tenth People's Hospital Affiliated to Tongji University, Gastroenterology, Shanghai, China, 8Inflammatory Bowel Disease Center, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Gastroenterology, Hangzhou, China

P483: Factors affecting the efficacy of granulomonocytapheresis in moderately-to-severely active ulcerative colitis: A multi-centre retrospective study

ECCO '19 Copenhagen

Year: 2019
Authors:

T. Yamamoto1, T. Iida2, K. Ikeya2, M. Kato2, A. Matsuura2, S. Tamura3, R. Takano3, S. Tani4, S. Osawa4, K. Sugimoto3, T. Shimoyama*1, H. Hanai2

1Yokkaichi Hazu Medical Centre, IBD Centre, Yokkaichi, Japan, 2Hamamatsu South Hospital, Center for Gastroenterology and Inflammatory Bowel Disease Research, Hamamastu, Japan, 3Hamamatsu University School of Medicine, First Department of Medicine, Hamamatsu, Japan, 4Hamamatsu University School of Medicine, Department of Endoscopic and Photodynamic Medicine, Hamamatsu, Japan

P484: Hepatitis B vaccination in inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Cortez Pinto*1, J. Castela1, J. Moleiro1, J. Pereira da Silva1, I. Rosa1, A. Dias Pereira1

1Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE, Gastroenterology, Lisboa, Portugal

P485: Prediction Model Incorporating Pharmacokinetics Calculates Probability of Endoscopic Healing in Patients with ulcerative colitis Starting Infliximab Therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Vande Casteele*1,2, V. Jairath2,3,4, J. Jeyarajah2, P. S. Dulai1,2, S. Singh1, B. G. Feagan2,3,4, W. J. Sandborn1,2

1University of California San Diego, Department of Medicine, La Jolla, USA, 2Robarts Clinical Trials, Inc., London, Canada, 3University of Western Ontario, Medicine, London, Canada, 4University of Western Ontario, Epidemiology and Biostatistics, London, Canada

P486: Faecal microbiota transplantation in inflammatory bowel disease: the patient's perspective

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Sousa*1, A. Ponte1, J. Rodrigues1, J. Silva1, C. Gomes1, A. Rodrigues1, A. P. Silva1, J. Carvalho1

1Centro Hospitalar de Vila Nova de Gaia e Espinho, Vila Nova de Gaia, Portugal

P487: Early vedolizumab trough levels are not associated with a short-term response in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

K. Pudilova1, M. Kolar1, D. Duricova*1, K. Malickova1,2, V. Hruba1, N. Machkova1, R. Vanickova1, K. Mitrova1, M. Lukas1, M. Vasatko1, M. Lukas1, M. Bortlik1,3,4

1ISCARE IVF, a.s., Clinical and Research Centre for IBD, Prague, Czech Republic, 2General University Hospital and First Faculty of Medicine, Charles University, Institute of Medical Biochemistry and Laboratory Medicine, Prague, Czech Republic, 3First Faculty of Medicine, Charles University and Military University Hospital, Department of Internal Medicine, Prague, Czech Republic, 4First Faculty of Medicine, Charles University, Institute of Pharmacology, Prague, Czech Republic

P488: Perianal Crohn's disease in the biological era

ECCO '19 Copenhagen

Year: 2019
Authors:

F. Pires*1, A. Carvalho1, D. Martins1, E. Cancela1, A. Silva1, P. Ministro1

1Centro Hospitalar Tondela Viseu, Gastrenterologia, Viseu, Portugal

P489: Defective anti-microbial peptides expression in Crohn’s disease mucosa can be reversed by strengthening IL-22 signalling

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Fantou*1,2, J. Martin1,2, A. Jarry3, A. Bourreille4,5, R. Josien1,2

1Centre de Recherche en Transplantation et Immunologie UMR 1064, Inserm, Université de Nantes, CHU Nantes, 44000, Nantes, France, 2Laboratoire d'Immunologie, CHU Nantes, 44000, Nantes, France, 3CRCINA, INSERM, Université d'Angers, Université de Nantes, 44000, Nantes, France, 4Institut des Maladies de l’Appareil Digestif (IMAD), CHU Nantes, 44000, Nantes, France, 5UMR 1235, Neuropathies entériques et pathologies digestives, Université de Nantes,, 44000, Nantes, France

P490: A vedolizumab population pharmacokinetic model including intravenous and subcutaneous formulations for patients with ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Rosario*1, D. Polhamus2, C. Chen1, W. Sun1, N. Dirks2

1Takeda Pharmaceuticals, Cambridge, USA, 2Metrum Research Group, Tariffville, USA

P491: INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel

ECCO '19 Copenhagen

Year: 2019
Authors:

O. Zmora*1, J. Panés2, C. Drohan3, J. M. Khalid4, S. Campbell-Hill4, C. Agboton5

1Assaf Harofeh Medical Center, Tel Aviv University, Department of Surgery, Tel Aviv, Israel, 2Hospital Clínic de Barcelona, Gastroenterology Department, Barcelona, Spain, 3Patient Advisor, County Dublin, Ireland, 4Takeda Development Centre, London, UK, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland

P492: Influence of the interval of time between the first and the second anti-TNF in the response to treatment in patients with inflammatory bowel disease

ECCO '19 Copenhagen

Year: 2019
Authors:

I. Baston*1, N. Mora-Cuadrado2, C. Calviño1, V. Mauriz-Barreiro1, D. De la Iglesia1, J. Gonzalez3, R. Ferreiro-Iglesias1, J. E. Dominguez-Munoz1, M. Barreiro-de Acosta1

1University Hospital, Gastroenterology, Santiago de Compostela, Spain, 2Clinic Hospital, Valladolid, Spain, 3University Hospital, Pharmacy, Santiago de Compostela, Spain

P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment

ECCO '19 Copenhagen

Year: 2019
Authors:

N. Bellil1, N. Bibani1, M. Sabbah1, D. Trad1, H. Elloumi1, A. Ouakaa*1, D. Gargouri1

1Habib Thameur Hospital, Gastroenterology, Tunis, Tunisia

P494: Regional survey on satisfaction with healthcare in inflammatory bowel disease patients

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Borzan1,2, V. Orsic Fric*1,2, B. Borzan2

1Clinical Hospital Centre Osijek, Department of Gastroenterology and Hepatology, Osijek, Croatia, 2University J.J. Strossmayer of Osijek, Faculty of Medicine, Osijek, Croatia

P495: Spacing the administration interval of anti-TNF agents: a valid strategy for patients with inflammatory bowel disease?

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Torres*1,2, L. Núñez3, A. Aguilar1, M. Mañosa1,4, F. Mesonero3, F. Cañete1,4, M. Calafat1, C. Fernandez3, E. Cabré1,4, A. López-Sanromán3, E. Domènech1,4

1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Institut d′Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain, 3Hospital Universitario Ramón y Cajal, Madrid, Spain, 4Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain

P496: Impact of ulcerative colitis on costs, work productivity and quality of life: a prospective study in a single referral centre

ECCO '19 Copenhagen

Year: 2019
Authors:

B. Scrivo*1, A. F. Aiello2, E. Giuffrida2, V. Calvaruso2, M. Cappello2

1University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy, 2Gastroenterology Section, DiBiMis, Palermo, Italy

P497: IL-33/ST2 levels and gut microbiota characterisation can predict mucosal response to anti-TNF therapy in ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

L. R. Lopetuso*1, V. Petito1, C. Graziani1, A. Quagliariello3, F. Del Chierico3, L. Putignani3, T. T. Pizarro4, A. Armuzzi1, F. Scaldaferri1, A. Gasbarrini1

1Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolical Sciences Department, Roma, Italy, 3Ospedale Pediatrico Bambino Gesù IRCCS, Unità per lo studio del Microbioma Umano, Roma, Italy, 4Case Western Reserve University, Cleveland, USA

P498: A nationwide quality improvement program in children with Crohn's disease improves outcomes within 12 months

ECCO '19 Copenhagen

Year: 2019
Authors:

D. Turner*1, C. Nehemia1, A. Yerushalmy-Feler2, A. Assa3, M. Slae4, M. Kori5, Y. Elenberg6, R. Shaoul7, E. Zifman8, H. Shamaly9, D. Berkowitz10, S. Peleg11, B. Yerushalmi12, E. Broide13, A. Aon14, O. Elkayam15, H. Bayan16, A. Gorodnichenko17, V. Pinsk18, D. Shouval19

1Shaare Zedek Medical Center, Jerusalem, Israel, 2Dana-Dwek Children's Hospital – Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3Schneider Children's Medical Center, Petah Tikva, Israel, 4Hadassah Medical Center, Jerusalem, Israel, 5Kaplan Medical Center, Rehovot, Israel, 6Carmel Medical Center, Haifa, Israel, 7Rambam Medical Center, Haifa, Israel, 8Meir Medical Center, Kfar Saba, Israel, 9Saint Vincent's Catholic Medical Center, Nazareth, Israel, 10Bnai Zion Medical Center, Haifa, Israel, 11HaEmek Medical Center, Afula, Israel, 12Soroka Medical Center, Beer-Sheva, Israel, 13Assaf Harofeh Medical Center, Be'er Ya'akov, Israel, 14Poriya Medical Center, Tiberias, Israel, 15Galilee Medical Center, Nahariya, Israel, 16Ziv Medical Center, Tsfat, Israel, 17Barzilai Medical Center, Ashkelon, Israel, 18Assuta Ashdod Medical Center, Ashdod, Israel, 19Sheba Medical Center, Ramat Gan, Israel

P499: Efficacy and safety of 2 or 3 vedolizumab intravenous infusions as induction therapy for ulcerative colitis and Crohn’s disease: results from VISIBLE 1 and 2

ECCO '19 Copenhagen

Year: 2019
Authors:

E. V. LoftusJr1, W. J. Sandborn2, D. Wolf3, S. Danese4, J. Chen5, X. Yao5, K. Kisfalvi*5, S. Vermeire6

1Mayo Clinic College of Medicine, Rochester, USA, 2University of California San Diego, La Jolla, USA, 3Atlanta Gastroenterology Associates, Atlanta, USA, 4Humanitas University, Milan, Italy, 5Takeda Development Center Americas Inc., Cambridge, USA, 6University Hospitals Leuven, Leuven, Belgium